CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Aggressive non-Hodgkin B cell lymphoma prognosis typically relies on the International Prognostic Index (IPI).
• Standard chemo-immunotherapy uses rituximab, which depends on CD16-mediated antibody-dependent cellular cytotoxicity (ADCC).
• This study investigates the role of CD16+ immune cells in patient prognosis.

Discussion:

• CD16+ T cells showed a superior progression-free survival (PFS) when above 1.6%, while CD16+ monocytes above 10.0% indicated inferior PFS.
• The negative impact of CD16+ monocytes was mitigated by the presence of CD16+ T cells.
• CD16+ T cells' protective function may stem from their potent ADCC capabilities.

Key Insights:

• Kaplan-Meier survival analysis revealed significant prognostic value for CD16+ T cell and CD16+ monocyte percentages.
• No correlation was found between CD16+ NK cells and patient survival.
• A combined model using CD16+ monocytes (>10%) and CD16+ T cells (<1.6%) achieved a Harrell's C index of 0.80 for relapse prediction.

Outlook:

• CD16 assessment in initial blood tests can serve as a precise marker for early relapse prediction in aggressive non-Hodgkin B cell lymphoma.
• Further research could explore therapeutic strategies targeting CD16+ cell populations.
• Validating these findings in larger patient cohorts is warranted.